Digistain vs Exer.ai

<p>Digistain is a sophisticated AI-enabled quantitative histopathology platform designed specifically for breast cancer risk stratification. It provides clinicians with fast, clear, and easy-to-interpret results, enabling personalized treatment planning for invasive breast cancer patients. By integrating seamlessly into existing histopathology workflows and operating on routine tissue samples, Digistain delivers risk assessments within an hour, significantly reducing wait times compared to traditional methods. </p> <p>You can rely on Digistain to help reduce treatment decision times and lower costs, making advanced recurrence risk prediction more accessible. Its technology captures detailed biopsy data and employs artificial intelligence to generate a precise prognostic score, supporting multidisciplinary team discussions without replacing clinical judgment.</p>

<p>Exer.ai offers a Clinical AI software platform that provides healthcare providers with objective motion analysis to improve clinical decision making. With real-time movement data, you can personalize treatment plans for operative, chronic, rehabilitation, and adaptive care. The platform benefits providers, patients, healthcare systems, and health plans by enabling earlier diagnosis, reducing costs, and supporting care coordination. It integrates easily into your workflows with apps for in-clinic scans, at-home patient use, real-time data portals, and automated reporting.</p> <p>The solution prioritizes privacy and compliance, being HIPAA compliant and FDA Class II registered as a medical device software. It works without additional hardware or wearables using any mobile device with proprietary AI neural networks, and integrates with EHR systems. Exer.ai supports multiple specialties including orthopedics, neurology, geriatrics, and more, helping you to deliver personalized, data-driven care and track patient progress remotely.</p>